Discovery Laboratories Inc., of Warrington, Pa., said third quarter sales of Surfaxin (lucinactant) to the company's specialty distributor totaled about $219,000 and said demand sales into hospitals grew about 60 percent to $116,000 compared to the second quarter of 2014.